GlassScriptPhysician profile
Elias A Dalloul
NPI 1316910912
$6,119.67
in general payments reported to CMS, 2019-2025
19 companies · $605 in 2025
The $605 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $909 · 2020: $119 · 2021: $115 · 2022: $668 · 2023: $3,145 · 2024: $558 · 2025: $605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,345 · Food and Beverage: $1,963.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,345.01 |
| Food and Beverage | $1,963.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,022.58 | 2022-2025 | Watchman Access System, Watchman Flx |
| Abbott Laboratories | $583.16 | 2022-2025 | Mitraclip, Gallant |
| Medtronic, INC. | $286.93 | 2024-2025 | Ffrangio, Signia |
| Janssen Pharmaceuticals, INC | $283.98 | 2019-2022 | |
| Biotronik INC. | $251.97 | 2025 | Solia, Amvia Edge, Acticor 7 Vr-T Dx |
| Edwards Lifesciences Corporation | $214.42 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.39 | 2019-2023 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $174.36 | 2020-2023 | Camzyos |
| Merck Sharp & Dohme LLC | $155.83 | 2023-2024 | Verquvo |
| Shockwave Medical, INC | $149.90 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Astrazeneca Pharmaceuticals LP | $138.63 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $125.19 | 2019 | |
| Lundbeck LLC | $124.74 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $120.53 | 2022 | |
| Amarin Pharma, INC. | $111.15 | 2019-2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $91.91 | 2019 | |
| Novo Nordisk INC | $31.15 | 2025 | Wegovy |
| Kiniksa Pharmaceuticals International, Plc | $21.75 | 2024 | Arcalyst |
| Arbor Pharmaceuticals, INC. | $18.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elias Dalloul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.